Silo Pharma Inc. is researching ibogaine-based treatments for traumatic brain injury and related conditions, aiming to address underserved health issues.

Silo Pharma Inc. highlights U.S. federal momentum backing the development of psychedelic-based therapies for mental health and substance use disorders, anticipating innovation in treating conditions such as PTSD and addiction.

Silo Pharma Inc. highlights U.S. federal actions advancing the development of psychedelic-based therapies for mental health and substance use disorders, anticipating innovation in PTSD and addiction treatment.

Optimi Health Corp. launches an Ibogaine Initiative to meet demand for pharmaceutical-grade ibogaine and expand its global strategy in psychedelic therapies, aligning with U.S. regulatory changes.

Helus Pharma(TM) and NRx Pharmaceuticals show support for the Executive Order promoting psychedelic therapies, emphasizing research acceleration and patient access.

Silo Pharma Inc. secures European patent for stress prevention methods, while NRx Pharmaceuticals works on ketamine labeling and supply in the U.S.

NRx Pharmaceuticals receives FDA approval for NRX-100 ketamine formulation for severe depression treatment based on existing clinical trial data, while NeuroThera Labs Inc. collaborates with Clearmind Medicine Inc. to develop a new non-hallucinogenic therapy for major depressive disorder.

Helus Pharma appoints Jill Conwell, a seasoned leader in the life sciences industry, to drive talent strategy and organizational development. Visit the company's newsroom for details.

Dr. Austin Harris of NeuroRelief Ketamine & Infusion Therapy in Los Angeles provides personalized ketamine treatment plans with high success rates, offering continuous support to patients.

NRx Pharmaceuticals has eliminated its balance sheet debt through an equity conversion, positioning the company to be debt-free by the end of 2025. Meanwhile, Cybin Inc. is transferring its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market, with common shares set to trade under the ticker symbol 'HELP' starting Jan. 5, 2026. Both companies are focused on advancing innovative mental health treatments and expanding their market presence.